INTRODUCTION {#sec1-1}
============

Despite growing population infertility is of great concern among many couples as it affects 10%-15% of reproductively active couples. Several causes of infertility such have male factors (20%-25%), anovulation (15%-20%), tubal defects (15%-40%), endometriosis (5%-10%), and unknown etiology (20%-30%) are documented.\[[@ref1]\] Clomiphene citrate is widely accepted as first line of ovulation-inducing agent. The advantages are low cost, easy administration, and high ovulation rate of 60%-80%. However, the disadvantage is low pregnancy rate of about 50%.\[[@ref2][@ref3]\] Letrozole, is a potent, highly specific nonsteroidal aromatase inhibitor with ovulation induction potential and high pregnancy rate of 80%, whichis due to its less antiestrogenic effect on endometrium.\[[@ref4]\] Previous studies have compared the efficacy of clomiphene citrate and letrozole among Western population; however, the data of comparing the efficacy of these two drugs among Indian population are lacking; hence, the present study was designed.

MATERIALS AND METHODS {#sec1-2}
=====================

The study was conducted in the infertility clinic of Mahatma Gandhi Medical College and Research Institute, Pondicherry, India, during June 2008 to December 2009. A detailed history was obtained from the infertile couple at first visit. Previous records if available were verified for the information such assemen analysis, tubal patency, hormonal assay, and use of any prior use of ovulation inducing agent/s. After ruling out male factor, tubal factor, local factor of infertility, the woman was followed through one natural cycle by transvaginal ultrasound (Wipro GE, Logiq 200, 6.5MHz transducer) for follicular development. Those who did not show the sign of follicular development by ultrasonography were randomized into two groups by using table of random number. Group 1 consisted of 25 women receiving 50 mg of clomiphene citrate from day 2 to day 6 and follicular monitoring was done from day 10 onward till day 18 on alternate days. Women, who did not show optimal follicular growth (20 mm), received 100 mg and 150 mg of clomiphene citrate in subsequent cycle for follicular development and were monitored for optimal follicular growth by transvaginal ultrasound. In Group 2, letrozole 2.5 mg was used from day 2 to day 6 and followed similarly to Group 1. Women, who did not show optimal follicular growth (20 mm), received 5 mg and 7.5 mg of letrozole in subsequent cycle. Person doing ultrasound was blinded for the drug patient received. Both the groups were followed-up for the number of follicles, diameter of large follicle, endometrial thickness, and serum estradiol levels. Women not responding to one drug were given the other drug but not included in the study.

RESULTS {#sec1-3}
=======

The mean ages (26.4 ± 3.55 and 27.72 ± 3.33 years) and body mass index (24.31 ± 1.27 and 24.43 ± 1.21kg/m^2^) of women were similar in Group 1 and Group 2, respectively. The numbers of patients with primary infertility were 21 and 22 in Group 1 and Group 2 respectively, while secondary infertility was observed in 4 and 3 patients from Group 1 and Group 2, respectively \[[Table 1](#T1){ref-type="table"}\].

###### 

Profile of the subjects
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Seven women had one follicle, seven women had two follicles, three women had three follicles, and one woman had four follicles in Group 1, while in Group 2 14 women had one follicle and only 3 women had two follicles. The mean numbers of follicles were 1.89 ± 0.9 and 1.18 ± 0.393 in Group 1 and Group 2, respectively. One woman of Group 1 had 4 follicles \[[Table 2](#T2){ref-type="table"}\]. The mean follicular diameter (20.67 ± 0.970 mm vs.20.76 ± 0.903 mm) was similar in Group 1 and Group 2, respectively \[[Table 2](#T2){ref-type="table"}\]. The mean endometrial thickness in Group 1 (7.47 ± 1.223 mm) and Group 2 (8.56 ± 1.375 mm) was not statistically different \[[Table 2](#T2){ref-type="table"}\]. The mean serum estradiol in Group 1 (437.5 ± 293.7 pg/mL) was significantly higher than Group 2 (291.82 ± 59.86 pg/mL) \[[Table 2](#T2){ref-type="table"}\].

###### 

Response to ovulation inducing agents
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DISCUSSION {#sec1-4}
==========

Most common treatable cause of infertility is anovulation. For last 40 years, the first line of treatment for women having anovulatory infertility was clomiphene citrate.\[[@ref5]\] Unfortunately, despite high rates of ovulation, pregnancy rates per cycle remain relatively low.\[[@ref4]\] Both thin endometrium and non-trilaminar pattern of the endometrium at midcycle are associated with low pregnancy rates and early pregnancy loss.\[[@ref6]\] For women who experienced these adverse effects with clomiphene citrate, the next optionis induction of ovulation with gonadotropin which increases both cost and risk to the woman. Alternatively, letrozole a potent aromatase inhibitor with excellent oral bioavailability and relatively short half-life is used for ovulation induction.\[[@ref5]\]

In our study, both the groups were comparable with respect to age and body mass index. Although previous studies\[[@ref6][@ref7][@ref8]\] reported similar ovulation rate by clomiphene citrate and/or letrozole, we observed higher ovulation rate in the clomiphene citrate group compared with letrozole-treated group. However, our results are compared to previous study reporting monofollicular development with letrozole.\[[@ref9]\] Nevertheless, we observed similarity in mean follicular diameter between the two groups which is concurrent to previous report.\[[@ref8]\]

Effect of clomiphene and letrozole on endometrium in ourstudy was comparable with study by Mitwally *et al*.,\[[@ref4][@ref10]\] who noted that women who had endometrial thickness of 5mm with clomiphene citrate responded well with 2.5 mg of letrozole and showed an increase in endometrial thickness up to 8 mm. Contrary to this, Fisher *et al*., and Kar\[[@ref6][@ref7]\] observed no difference of endometrial thickness in their study.

Estimation of serum estradiol is important especially to know the quality of ovum, and for administration of human gonadotrophin (hCG) in cases of stimulated cycle. However, high serum estradiol predisposes to hyperstimulation syndrome. Although human gonadotrophin was not used in our study, we estimate serum estradiol to know the antiestrogenic property of clomiphene citrate and letrozole. Concurrent to previous reports\[[@ref6][@ref10]\] we observed a significantly higher serum estradiol levels in clomiphene citrate-treated group.

Although the numbers of follicles developed per cycle by using clomiphene citrate was higher; nevertheless, it increases the chances of ovarian hyperstimulation syndrome and multiple pregnancy. However, in our study no multiple pregnancy was noted. Interestingly, Kar\[[@ref7]\] also showed monofolliculogenesis similar to our study; however, the pregnancy rate was higher in letrozole group in contrast to clomiphene group.\[[@ref7]\] This result may be due to increase resistance to the clomiphene in polycystic ovarian syndrome (PCOS). In contrast, our study response to the clomiphene was good as none of our cases were PCOS.

On the basis of our study we conclude that clomiphene citrate should be considered as first line of drug and failing which letrozole may be tried as alternative. We acknowledge small sample size as limitation of our study and warrant future studies with larger sample size to the compare the efficacy of clomiphene citrate and letrozole.
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